Clinical trial
Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer
NCT05306847
Study timeline
Study start (estimated)2022-04-01Date precision: day
Registry last updated2022-04-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Carcinoma, Non-Small-Cell Lungunresolved
Interventions
SintilimabDRUG
AnlotinibDRUG
Sponsors & collaborators
Peking Union Medical College Hospitallead sponsor
Xinda Biopharmaceutical Groupcollaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.collaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05306847 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.